Virginia Commonwealth University

VCU Massey Cancer Center

2011 Archive

New therapy for blood cancers developed

Clinical researchers at VCU Massey Cancer Center have successfully completed a phase 1 clinical trial evaluating a combination of the drugs Bortezomib and Alvocidib in patients with relapsed or refractory blood cancers, paving the way for a phase 2 clinical trial to test the safety and effectiveness of the new therapy.

Continue reading →

Massey physicians recognized as Top Docs by Richmond Magazine

Physicians at Virginia Commonwealth University Massey Cancer Center were reported as “Top Docs” in Richmond Magazine’s April 2011 issue. Honored with this recognition were 24 of Massey’s doctors. These selections were the result of a survey that asked Richmond-area physicians whom they would recommend in a range of specialties. Several of Massey’s doctors appeared in more than one category.

Continue reading →

VCU Massey Cancer Center recognized by U.S. News as Richmond’s only nationally ranked cancer care provider

Virginia Commonwealth University Massey Cancer Center provides the only nationally ranked cancer care in Richmond, Va., according to U.S. News & World Report. For the first time, U.S. News ranked the hospitals in America’s 52 largest metropolitan areas. Ranking at the top of all 20 hospitals in the Richmond metro area is VCU Medical Center, which includes Massey’s oncology patient care.

Continue reading →

New biomarker predicts breast cancer relapse

Researchers from Virginia Commonwealth University Massey Cancer Center have discovered a new biomarker related to the body’s immune system that can predict a breast cancer patient’s risk of cancer recurrence. This breakthrough may lead to new genetic testing that further personalizes breast cancer care.

Continue reading →

New combination therapy eradicates prostate cancer in vivo

Paul Fisher

In their study, published in the journal Proceedings of the National Academy of Sciences, prostate cancer growth in mice with functioning immune systems was inhibited by sensitizing the cancer cells with the drug Sabutoclax (BI-97C1) and using UTMD technology to deliver a viral gene therapy that expresses the genemda-7/IL-24. This powerful new approach to treating prostate cancer builds upon prior studies by principle investigator Paul B. Fisher, M.P.H., Ph.D., Thelma Newmeyer Corman Endowed Chair in Oncology Research at VCU Massey (photo on left). Fisher is professor and chair of the Department of Human and Molecular Genetics in the VCU School of Medicine, and director of the VCU Institute of Molecular Medicine.

Continue reading →